Influence of Forkhead box Q1 expression on therapeutic effect of transarterial chemoembolization after hepatocellular carcinoma surgery

Influence of Forkhead box Q1 expression on therapeutic effect of transarterial chemoembolization after hepatocellular carcinoma surgery

ObjectiveTo investigate the expression of Forkhead box Q1 (FOXQ1) in the tissue of hepatocellular carcinoma (HCC), its influence on the prognosis of surgical resection combined with transarterial chemoembolization (TACE), and the value of FOXQ1 in evaluating the treatment outcome of HCC. MethodsA to...

Full description

Bibliographic Details
Main Authors:	ZHOU Yilong, CHEN Yuan, ZHANG Yixin
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Clinical Hepatology 2016-11-01
Series:	Linchuang Gandanbing Zazhi
Online Access:	http://www.lcgdbzz.org/qk_content.asp?id=7819

Similar Items

Transarterial chemoembolization for hepatocellular carcinoma in Fontan surgery patient
by: Antonio Orlacchio, M.D., et al.
Published: (2020-12-01)

Treatment Strategy of Transarterial Chemoembolization for Hepatocellular Carcinoma
by: Shiro Miyayama
Published: (2020-10-01)

Transarterial chemoembolization with drug-eluting beads versus conventional transarterial chemoembolization in locally advanced hepatocellular carcinoma
by: Baur J, et al.
Published: (2016-06-01)

Lipiodol retention pattern predicts transarterial chemoembolization therapeutic effect in hepatocellular carcinoma
by: Margaretha Vianny, et al.
Published: (2015-04-01)

Lipiodol retention pattern predicts transarterial chemoembolization therapeutic effect in hepatocellular carcinoma
by: Margaretha Vianny, et al.
Published: (2016-02-01)

Outcome of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
by: Hadeel A Helmi, et al.
Published: (2020-01-01)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.
by: Jonggi Choi, et al.
Published: (2020-01-01)

Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres
by: Waleed M. Hetta, et al.
Published: (2014-09-01)

Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Predictors of Survival
by: Summit Sawhney, et al.
Published: (2011-01-01)

Healthcare costs of transarterial chemoembolization in the treatment of hepatocellular carcinoma
by: Fateen W, et al.
Published: (2017-10-01)

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
by: Sacco R, et al.
Published: (2017-07-01)

PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma
by: Sean P. Martin, et al.
Published: (2020-06-01)

Expression and clinical significance of forkhead box A2 and forkhead box J2 in hepatocellular carcinoma
by: RAN Xiaoke
Published: (2021-06-01)

Factors Predicting Survival after Transarterial Chemoembolization of Unresectable Hepatocellular Carcinoma
by: Farina M. Hanif, et al.
Published: (2014-10-01)

Spontaneous regression of lung metastases after transarterial chemoembolization for hepatocellular carcinoma
by: Naoko Kakuta, MD, et al.
Published: (2021-06-01)

A Rare Complication Following Transarterial Chemoembolization for Hepatocellular Carcinoma
by: Wei-Chen Lin, et al.
Published: (2015-12-01)

Tumor Response Evaluation Transarterial Chemoembolization-treated Hepatocellular Carcinoma
by: Juferdy Kurniawan
Published: (2016-05-01)

Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
by: Qunfang Zhou, et al.
Published: (2020-11-01)

Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis
by: Lv WF, et al.
Published: (2018-10-01)

Dual input computed tomography perfusion in evaluating the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma
by: Logain Nabil Salem, et al.
Published: (2018-09-01)

Forkhead Box S1 Inhibits the Progression of Hepatocellular Carcinoma
by: Lei D, et al.
Published: (2020-11-01)

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.
by: Mi Young Jeon, et al.
Published: (2019-01-01)

A Rare Case of Empyema Developed after Transarterial Chemoembolization for Hepatocellular Carcinoma
by: Young Keun Sur, et al.
Published: (2015-01-01)

Rupture of Hepatocellular Carcinoma after Transarterial Chemoembolization followed by Massive Gastric Bleeding
by: Kazuhiro Nishida, et al.
Published: (2018-01-01)

Acute necrotizing pancreatitis after transarterial chemoembolization of hepatocellular carcinoma: an usual complication
by: Juan Manuel Alcívar-Vásquez, et al.
Published: (2014-02-01)

Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization
by: Xiaofei Yue, et al.
Published: (2021-05-01)

Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
by: Hao Hu, et al.
Published: (2014-01-01)

Balloon-occluded transarterial chemoembolization for hepatocellular carcinoma: History, background, and the roles
by: Toshiyuki Irie, et al.
Published: (2020-01-01)

Radiological response in Saudi patients undergoing transarterial chemoembolization for hepatocellular carcinoma
by: Al Fuhaid Turki, et al.
Published: (2007-01-01)

Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma
by: WU Lei, et al.
Published: (2018-04-01)

Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma
by: Ying Zhao, et al.
Published: (2021-03-01)

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma
by: Liu KC, et al.
Published: (2020-08-01)

Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma
by: Shuling Chen, et al.
Published: (2019-04-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang W, et al.
Published: (2021-07-01)

Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients
by: In Joon Lee, et al.
Published: (2019-08-01)

Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma
by: Lei Chen, et al.
Published: (2020-06-01)

Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres® Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: A Meta-Analysis
by: Bin Liang, et al.
Published: (2021-03-01)

Potential prognostic factors for solitary hepatocellular carcinoma ≤ 5 cm after transarterial chemoembolization
by: Soon Young Ko, et al.
Published: (2019-11-01)

Gallbladder Perforation after Transarterial Chemoembolization in a Patient with a Huge Hepatocellular Carcinoma
by: Min Young Son, et al.
Published: (2020-07-01)

Risk Factors for the Development of Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment
by: Mariana Lima, et al.
Published: (2018-01-01)